A detailed history of Citigroup Inc transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Citigroup Inc holds 39,692 shares of ELEV stock, worth $21,036. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,692
Previous 11,491 245.42%
Holding current value
$21,036
Previous $31,000 25.81%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.56 - $3.02 $15,792 - $85,167
28,201 Added 245.42%
39,692 $23,000
Q2 2024

Aug 12, 2024

SELL
$2.35 - $5.17 $253,839 - $558,447
-108,017 Reduced 90.38%
11,491 $31,000
Q1 2024

May 10, 2024

BUY
$0.59 - $5.13 $70,509 - $613,076
119,508 New
119,508 $613,000
Q3 2023

Nov 09, 2023

BUY
$0.65 - $1.56 $11,927 - $28,626
18,350 New
18,350 $12,000

Others Institutions Holding ELEV

About Elevation Oncology, Inc.


  • Ticker ELEV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,300,900
  • Market Cap $12.3M
  • Description
  • Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...
More about ELEV
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.